

Annika Herlemann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8178582/publications.pdf>

Version: 2024-02-01

37
papers

939
citations

516215

16
h-index

454577

30
g-index

38
all docs

38
docs citations

38
times ranked

1555
citing authors

#	ARTICLE	IF	CITATIONS
1	Active surveillance in intermediate-risk prostate cancer with PSA 10–20 ng/mL: pathological outcome analysis of a population-level database. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 690-693.	2.0	8
2	Total Tumor Volume on 18F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with 225Ac-PSMA-I&T. <i>Biomedicines</i> , 2022, 10, 946.	1.4	6
3	How Often Does Magnetic Resonance Imaging Detect Prostate Cancer Missed by Transrectal Ultrasound?. <i>European Urology Focus</i> , 2021, 7, 1268-1273.	1.6	6
4	Influence of pelvic lymph node dissection and node-positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer. <i>Prostate</i> , 2021, 81, 102-108.	1.2	6
5	Feasibility of Different Tumor Delineation Approaches for 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 663631.	1.3	7
6	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. <i>European Urology</i> , 2021, 79, 717-721.	0.9	13
7	Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 136-143.	2.0	36
8	Pretreatment Risk Stratification Tools for Prostate Cancer—Moving from Good to Better, Toward the Best. <i>European Urology</i> , 2020, 77, 189-190.	0.9	2
9	The Relative Impact of Urinary and Sexual Function vs Bother on Health Utility for Men With Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa044.	1.4	0
10	Inhibition of neurogenic and thromboxane A ₂ -induced human prostate smooth muscle contraction by the integrin $\alpha 2\beta 1$ inhibitor BTT-3033 and the integrin-linked kinase inhibitor Cpd22. <i>Prostate</i> , 2020, 80, 831-849.	1.2	11
11	The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations. <i>European Urology</i> , 2020, 78, 335-344.	0.9	28
12	Inhibition of Female and Male Human Detrusor Smooth Muscle Contraction by the Rac Inhibitors EHT1864 and NSC23766. <i>Frontiers in Pharmacology</i> , 2020, 11, 409.	1.6	11
13	Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US. <i>JAMA Network Open</i> , 2020, 3, e2031349.	2.8	41
14	A NAV2729-sensitive mechanism promotes adrenergic smooth muscle contraction and growth of stromal cells in the human prostate. <i>Journal of Biological Chemistry</i> , 2019, 294, 12231-12249.	1.6	16
15	Editorial: Conversion to negative surgical margin after intraoperative frozen section “(un)necessary effort and relevance in 2019?”. <i>BJU International</i> , 2019, 123, 744-746.	1.3	1
16	New strategies for inhibition of non-adrenergic prostate smooth muscle contraction by pharmacologic intervention. <i>Prostate</i> , 2019, 79, 746-756.	1.2	16
17	Chrelin Aggravates Prostate Enlargement in Rats with Testosterone-Induced Benign Prostatic Hyperplasia, Stromal Cell Proliferation, and Smooth Muscle Contraction in Human Prostate Tissues. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-14.	1.9	9
18	Health Care Delivery for Metastatic Hormone-sensitive Prostate Cancer Across the Globe. <i>European Urology Focus</i> , 2019, 5, 155-158.	1.6	13

#	ARTICLE	IF	CITATIONS
19	Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. <i>European Urology</i> , 2019, 75, 176-183.	0.9	101
20	The increase of stage, grading, and metastases in patients undergoing radical prostatectomy during the last decade. <i>World Journal of Urology</i> , 2019, 37, 1103-1109.	1.2	7
21	Inhibition of human prostate smooth muscle contraction by the LIM kinase inhibitors, SR7826 and LIMKi3. <i>British Journal of Pharmacology</i> , 2018, 175, 2077-2096.	2.7	20
22	Inhibition of prostatic smooth muscle contraction by the inhibitor of G protein-coupled receptor kinase 2/3, CMPD101. <i>European Journal of Pharmacology</i> , 2018, 831, 9-19.	1.7	10
23	Community-based Outcomes of Open versus Robot-assisted Radical Prostatectomy. <i>European Urology</i> , 2018, 73, 215-223.	0.9	45
24	Inhibition of smooth muscle contraction and ARF6 activity by the inhibitor for cytohesin GEFs, secinH3, in the human prostate. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, F47-F57.	1.3	11
25	Inhibition of Prostate Smooth Muscle Contraction by Inhibitors of Polo-Like Kinases. <i>Frontiers in Physiology</i> , 2018, 9, 734.	1.3	8
26	Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. <i>Radiation Oncology</i> , 2018, 13, 37.	1.2	54
27	Perioperative patient education improves long-term satisfaction rates of low-risk prostate cancer patients after radical prostatectomy. <i>World Journal of Urology</i> , 2017, 35, 1205-1212.	1.2	18
28	Non-Adrenergic, Tamsulosin-Insensitive Smooth Muscle Contraction is Sufficient to Replace Adrenergic Tension in the Human Prostate. <i>Prostate</i> , 2017, 77, 697-707.	1.2	30
29	Postoperative upgrading of prostate cancer in men ≥ 75 years: a propensity score-matched analysis. <i>World Journal of Urology</i> , 2017, 35, 1517-1524.	1.2	17
30	“Finding the needle in a haystack” oncologic evaluation of patients treated for LUTS with holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP). <i>World Journal of Urology</i> , 2017, 35, 1777-1782.	1.2	35
31	Inhibition of agonist-induced smooth muscle contraction by picotamide in the male human lower urinary tract outflow region. <i>European Journal of Pharmacology</i> , 2017, 803, 39-47.	1.7	13
32	Whom to Treat. <i>Urologic Clinics of North America</i> , 2017, 44, 547-555.	0.8	5
33	Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy. <i>Oncotarget</i> , 2017, 8, 44131-44140.	0.8	16
34	Salvage lymph node dissection after ^{68}Ga -PSMA or ^{18}F -FEC PET/CT for nodal recurrence in prostate cancer patients. <i>Oncotarget</i> , 2017, 8, 84180-84192.	0.8	41
35	Inhibition of Adrenergic and Non-Adrenergic Smooth Muscle Contraction in the Human Prostate by the Phosphodiesterase 10-Selective Inhibitor TC-E 5005. <i>Prostate</i> , 2016, 76, 1364-1374.	1.2	11
36	Smooth muscle contraction and growth of stromal cells in the human prostate are both inhibited by the Src family kinase inhibitors, AZM475271 and PP2. <i>British Journal of Pharmacology</i> , 2016, 173, 3342-3358.	2.7	19

#	ARTICLE	IF	CITATIONS
37	<p>⁶⁸Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. <i>European Urology</i>, 2016, 70, 553-557.</p>	0.9	248